Amarin Corp Plc (AMRN)

[dogn]

AMRN makes the American Association of Individual Investors (AAII) list of 4 Undervalued Biotechnology & Medical Research Stocks for Thursday, September 14

https://www.aaii.com/investingideas/article/86607-4-undervalued-biotechnology--medical-research-stocks-for-thursday-september-14

Someone needs to let the author know about the Reduce-It CVD indication!

dogn

If you’re not a robot you can read:
Featured Tickers:
AMRN
BWV
NEXI
SYBX
Based on key financial metrics such as the price-to-sales ratio, shareholder yield and the price-earnings ratio, the following 4 stocks made the list for top value stocks in the Biotechnology & Medical Research industry. Those looking for value stocks to add to their portfolio may want to use this list as a starting point for further investment research.

Amarin Corporation plc (ADR)’s Value Grade: B

Metric Score AMRN Industry Median
Price/Sales 40 1.16 7.89
Price/Earnings na na 20.6
EV/EBITDA na na 0.8
Shareholder Yield 68 (2.4%) (7.4%)
Price/Book Value 18 0.71 1.54
Price/Free Cash Flow na na 22.7

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are value and so on.

Amarin Corporation plc (ADR) has a Value Score of 62, which is considered to be undervalued.

When you look at Amarin Corporation plc (ADR)’s price-to-sales ratio at 1.16 compared to the industry median at 7.89, this company has a lower price relative to revenue compared to its peers. This could make Amarin Corporation plc (ADR)’s stock more attractive for value investors.

Shareholder yield is the sum of a stock’s dividend yield (paid over previous 12 months minus special dividends) and the percentage of net share buybacks over the previous 12 months. Amarin Corporation plc (ADR)’s shareholder yield is higher than its industry median ratio of (7.45%). Value investors may look for an attractive shareholder yield because it can be a powerful tool for identifying if the company has a good management team.

As one of the most common value metrics, the price-to-book ratio evaluates a company’s current market price relative to its book value. Amarin Corporation plc (ADR)’s price-to-book ratio is lower than its industry median ratio of 1.54. This could make Amarin Corporation plc (ADR) more attractive to investors looking for a new addition to their portfolio.